Thymulin
Also known as: FTS · facteur thymique sérique · zinc-thymulin
A zinc-bound nonapeptide thymic hormone with distinctive research applications spanning immune-cognitive research, sickness-behaviour research, and neuroinflammation-mediated cognitive-decline contexts.
Thymulin (FTS) is a zinc-bound nonapeptide thymic hormone with distinctive immune-cognitive research applications spanning sickness-behaviour and neuroinflammation contexts.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Neuroprotection
- Half-life
- Short plasma half-life; sustained pharmacodynamic effects on immune tone
Section 1
Overview
Thymulin (also known as FTS, from the French facteur thymique sérique) is a nonapeptide thymic hormone that requires zinc-binding for biological activity — its zinc-bound form is the pharmacologically active species. It was originally identified in the 1970s as the thymic peptide responsible for T-cell maturation effects, and has since been characterised for a range of immunomodulatory, neuroendocrine, and cognitive-relevance research applications.
The compound's cognitive-relevance research context emerges from the immune-cognitive research field. Immune-system-mediated cognitive effects — the 'sickness behaviour' framework, cytokine-mediated cognitive decline, and inflammaging-mediated cognitive-ageing contributions — are all research contexts where an immunomodulatory peptide with CNS effects provides research-tool relevance. Thymulin's distinctive zinc-dependence adds a research-tool angle for probing zinc-immune-cognitive interactions specifically.
Direct current research use of thymulin is specialised rather than mainstream. The compound retains research-tool relevance for immune-cognitive research applications and provides completion of the thymic-peptide-family coverage on this reference alongside the more widely-used Thymalin preparation.
Section 2
Discovery & History
- Identified in the 1970s by Bach and colleagues as the thymic serum factor responsible for T-cell maturation effects.
- The zinc-binding requirement for biological activity was characterised subsequently, distinguishing thymulin from other thymic peptide preparations.
- Extensively characterised through the 1980s and 1990s for immunomodulatory effects across multiple experimental models.
- Research applications extended into neuroinflammation, sickness-behaviour, and immune-cognitive research contexts through the 2000s and 2010s.
- Not licensed as a medicine in any major jurisdiction; remains a research chemical.
Section 3
Mechanism of Action
- 1Zinc-dependent binding to thymulin receptors on T-cell and other immune-cell populations, mediating T-cell maturation and immunomodulatory effects.
- 2Modulation of pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) via effects on macrophage and lymphocyte activation state.
- 3Anti-inflammatory effects in preclinical models of inflammatory disease, providing the mechanistic scaffold for the immune-cognitive research applications.
- 4Reported effects on sickness-behaviour phenotype in preclinical models — reduced cytokine-mediated cognitive and behavioural effects in lipopolysaccharide-driven sickness models.
- 5Effects on the hypothalamic-pituitary-adrenal (HPA) axis via central immune-endocrine interactions.
- 6Modulation of microglial activation and neuroinflammation in preclinical CNS-injury and neurodegenerative disease models.
- 7Reported effects on cognitive endpoints in aged and immunocompromised research populations, extending the immune-cognitive research application angle.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Distinctive zinc-dependent immunomodulatory mechanism providing a research-tool niche unshared by other peptides on this reference.
- 2Immune-cognitive research applications relevant to inflammaging and neuroinflammation-mediated cognitive decline research.
- 3Sickness-behaviour research applications providing a specific research-tool angle for probing cytokine-mediated cognitive effects.
- 4Substantial preclinical characterisation across immunomodulatory, neuroendocrine, and cognitive contexts.
- 5Well-characterised acute-safety profile from decades of academic research use.
- 6Zinc-dependence adds a research-tool angle for probing zinc-immune-cognitive interactions specifically.
- 7Complements the Thymalin coverage on this reference by extending the thymic-peptide family with a defined-nonapeptide research tool.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / parenteral (research) | Microgram-range doses in preclinical research protocols | Variable across research protocols | Course lengths vary from days to weeks in most research contexts |
Note: Research protocol standardisation for thymulin specifically is limited; the compound's specialised research applications rather than mainstream research-community usage limit the availability of standardised research protocols.
Section 6
Administration Routes
- Subcutaneous injection in most research contexts.
- Intraperitoneal administration in animal research contexts.
- Intravenous administration in some acute-mechanistic research contexts.
- Oral administration produces limited bioavailability given the nonapeptide structure.
Section 7
Safety Profile
Commonly reported
- · Well-tolerated in preclinical research at studied doses.
- · Injection-site reactions with parenteral administration.
- · Occasional mild transient effects during initial administration.
- · No dependence, tolerance, or withdrawal phenomena documented in the reported research base.
Rare / theoretical
- · Long-term safety data is limited given the compound's specialised research use.
- · Theoretical interactions with immunosuppressive or immunomodulatory pharmaceuticals.
- · Rare hypersensitivity reactions.
- · Zinc-status-dependent activity may complicate research-context interpretation in zinc-deficient contexts.
Contraindications
- · Not authorised for human use in the UK.
- · Pregnancy and lactation — no controlled data.
- · Active severe autoimmune disease — theoretical contraindication via the immunomodulatory mechanism.
- · Concurrent use with immunosuppressive pharmaceuticals should be evaluated for interaction.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Research chemical only.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
Thymulin foundational characterisation as thymic serum factor
The classical 1970s Bach-laboratory identification and characterisation of thymulin as the thymic serum factor responsible for T-cell maturation effects, establishing the compound's foundational immunological research context and providing the mechanistic scaffold for subsequent research applications.
Thymulin zinc-dependence characterisation
Molecular characterisation of thymulin's zinc-binding requirement for biological activity, distinguishing the zinc-bound active form from the zinc-free inactive form and establishing the distinctive zinc-immune interaction mechanism-of-action framework.
Thymulin in sickness-behaviour research
Research applications of thymulin in sickness-behaviour research contexts, reporting reduced cytokine-mediated cognitive and behavioural effects in lipopolysaccharide-driven sickness models. Provides the immune-cognitive research application angle relevant to inflammation-mediated cognitive decline research.
Thymulin in neuroinflammation and cognitive-ageing research
Preclinical research applications of thymulin in neuroinflammation and cognitive-ageing research contexts, reporting anti-inflammatory effects in CNS injury models and cognitive-endpoint improvements in aged research populations. Extends the immune-cognitive research application angle into cognitive-ageing contexts.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Thymulin for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Thymulin from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.